Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

Inclusion Criteria: Follow-on Participants * Subjects from Finland and Poland previously enrolled in study V102\_15 (NCT02212457) who have received all planned meningococcal vaccinations in the study * Who have not received any additional meningococcal vaccination since the last meningococcal vaccination administered in the parent trial. * Who have given written informed consent or assent after the nature of the study has been explained according to local regulatory requirements, prior to study entry. If the subject is under age 18 at the time of enrollment, the parent(s)/ legal guardian(s) of the subject should have given their written consent. * Individuals of who the investigator believes can and will comply with the requirements of the protocol. * Individuals in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator. Naive Group * Male and female individuals of similar age (approximately 12-20 years) to follow-on subjects from V102\_15 (NCT02212457) trial. * Who have not received any meningococcal vaccination since birth * Individuals who have given their written informed consent or assent after the nature of the study has been explained according to local regulatory requirements, prior to study entry. If the subject is under age 18 at the time of enrollment, the parent(s)/ legal guardian(s) of the subject should have given their written consent. * Individuals of who the investigator believes can and…